Long-term safety of filgrastim administration
Author Information
Author(s): Confer Dennis L, Miller John P
Primary Institution: National Marrow Donor Program
Hypothesis
Does filgrastim exposure increase the risk of developing acute leukaemia in donors?
Conclusion
No long-term risks have been found so far in donors who received filgrastim for PBSC mobilisation.
Supporting Evidence
- Among 4015 donors, 20 cases of cancer were reported, consistent with expected rates.
- There have been no reports of leukaemia or lymphoma in the donor cohort.
- Normal individuals are at risk for developing cancer throughout their lifetime.
Takeaway
This study looked at people who donated stem cells and found that using a drug called filgrastim didn't seem to cause any long-term health problems.
Methodology
Follow-up of PBSC donors who received filgrastim, with annual monitoring for cancer development.
Potential Biases
Potential bias due to the self-reported nature of cancer occurrences.
Limitations
The long-term effects of filgrastim are still being studied, and the data is limited.
Participant Demographics
Volunteer, unrelated adult donors of PBSC.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website